Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) drives global healthcare innovation through its pharmaceutical, medical technology, and consumer health divisions. This dedicated news hub provides investors and industry professionals with essential updates on regulatory developments, research breakthroughs, and strategic initiatives from one of healthcare's most diversified leaders.
Access real-time press releases and curated analysis covering FDA approvals, clinical trial results, and market expansion efforts. Our repository simplifies tracking JNJ's progress in oncology, immunology, and surgical advancements while maintaining perspective on its long-term corporate strategy.
Key updates include earnings disclosures, product pipeline milestones, and partnership announcements that demonstrate JNJ's commitment to addressing complex health challenges. Bookmark this page for streamlined access to verified information supporting informed decisions about this Dow Jones Industrial Average component.
Johnson & Johnson (NYSE: JNJ) will conduct a conference call on October 19, 2021, at 8:30 a.m. ET to review its third-quarter results. Hosted by Joseph J. Wolk, CFO, the call will feature key executives including Ashley McEvoy and Jennifer Taubert. Access the call via www.investor.jnj.com or by phone at 877-869-3847 (U.S.) and 201-689-8261 (international). Replay options will be available until November 2. The press release will be accessible at 6:45 a.m. ET that day.
On September 13, 2021, Johnson & Johnson (NYSE: JNJ) announced promising results for its Ebola vaccine regimen, Zabdeno® and Mvabea®, published in The Lancet Infectious Diseases. The Phase 3 EBOVAC-Salone study showed robust antibody responses in adults and children, persisting for at least two years. Booster doses further enhanced immune responses within a week. Conducted in Sierra Leone, the study demonstrated no safety concerns. The vaccine, granted EU marketing authorization in July 2020, aims to prevent future Ebola outbreaks, highlighting Johnson & Johnson's commitment to global public health.
Johnson & Johnson faces legal challenges as women with ovarian cancer seek a temporary restraining order against the company. They allege that J&J plans to transfer about $24 billion in potential talc-related liabilities to a subsidiary to seek bankruptcy protection, potentially limiting victim compensation. This move may halt ongoing litigation on a national scale. The legal strategy, known as the 'Texas Two-Step,' is seen as a way to evade financial responsibility. Critics argue that this abuse of bankruptcy threatens victims' rights to fair trials.
On August 26, 2021, a California jury awarded $26.5 million to a woman whose mesothelioma was linked to Johnson & Johnson's talcum powder products. This verdict adds to a growing trend of jury findings against J&J concerning the carcinogenic nature of talc. Reports reveal that a significant percentage of talc-based products sold by the company contained asbestos, which J&J allegedly concealed from the public and regulators. The company has indicated intentions to bundle such liabilities into a separate entity and pursue bankruptcy protection, raising concerns about accountability for victims.
Johnson & Johnson (NYSE: JNJ) announced that its Phase 2b Imbokodo HIV vaccine trial did not provide sufficient protection against HIV in young women in sub-Saharan Africa. While the vaccine showed a favorable safety profile, with no serious adverse events, the study will not continue. The trial involved over 2,600 participants, and the primary analysis indicated a vaccine efficacy of 25.2%, which was not statistically significant. Ongoing research from this trial may aid future HIV vaccine development. J&J continues its Phase 3 Mosaico study, testing a different vaccine regimen in men and transgender individuals.
Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on September 28, 2021. Mathai Mammen, Global Head of Research & Development at Janssen, and Scott White, Company Group Chairman of NA Pharmaceuticals, will represent the company in a session at 10:00 a.m. ET.
The live webcast can be accessed via the Johnson & Johnson website, with a replay available 48 hours post-event.
Johnson & Johnson (NYSE: JNJ) announced promising data supporting the use of its COVID-19 vaccine as a booster for individuals previously vaccinated with its single-shot vaccine. Interim findings show that a booster dose significantly increases spike-binding antibodies by nine-fold compared to 28 days post-primary vaccination. The company is working with health authorities to discuss potential booster strategies. These results follow earlier Phase 1/2a studies demonstrating strong antibody responses lasting eight months post-vaccination.
Ovarian cancer victims are seeking a court order to prevent Johnson & Johnson (NYSE:JNJ) from moving its $500 billion assets to a subsidiary and declaring bankruptcy. This tactic, referred to as the "Texas Two-Step," aims to shield J&J from over $17 billion in liabilities linked to talc-cancer lawsuits.The plaintiffs argue that this move constitutes fraudulent conveyance, potentially halting over 34,000 claims. A trial in Missouri is scheduled for September 7, raising concerns over the implications for personal injury claimants if J&J's plan proceeds.
On August 19, 2021, Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition into the role of Executive Chairman while Joaquin Duato, currently Vice Chairman, will become CEO, effective January 3, 2022. Gorsky has led the company as CEO since 2012, overseeing a 60% increase in R&D investments, reaching $12 billion in 2020. He emphasized the company's strong performance across all segments. Duato expressed enthusiasm for leading the company, highlighting its unmatched healthcare platform. The Board acknowledged the effective succession planning that enabled this leadership transition.
On August 12, 2021, Johnson & Johnson (NYSE: JNJ) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 15, 2021. The company will be represented by Joseph J. Wolk, Executive Vice President and CFO, and Mathai Mammen, Global Head of Research & Development, during a session at 9:30 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website, with a replay available 48 hours post-event.
